Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall, the AI-generated claims show substantial misalignment with the FDA label. A minority of statements are supported or partially supported; the majority are not supported by the labeling, including several dosing, comparative, and off-label-type assertions.
Category Scores
Accurate Statements
Insomnia is an adverse reaction to Prozac and can occur early in treatment.
5.10 (Anxiety and Insomnia)
Prozac has a long elimination half-life (4-6 days) after chronic dosing.
12.3 (Pharmacokinetics)
Serotonin syndrome is a safety concern and can occur with serotonergic drugs; monitoring is advised.
5.2 (Serotonin Syndrome)
Unsupported Statements
Prozac (fluoxetine) commonly causes insomnia, especially during the first weeks of use.
Label supports insomnia as an adverse reaction but the specific claim of 'commonly' and the first-week timing is not explicitly stated in the provided sections; although 5.10 discusses insomnia, the extracted claim itself is not directly confirmed as written in the label.
This side effect occurs in 10-20% of patients in clinical trials.
The exact overall incidence percentage is not provided in the labeled excerpts; percentages vary by indication and study.
It is often described as activation symptoms from its stimulating effects on serotonin.
Label uses terms like 'anxiety and insomnia' but does not characterize insomnia as 'activation symptoms' due to stimulating serotonin effects in this phrasing.
It typically peaks in the initial 1-2 weeks before improving as the body adjusts.
Label does not specify a peak-and-improve time course for insomnia symptoms in this manner.
Prozac boosts serotonin more potently than some SSRIs.
Label does not provide comparative potency statements across SSRIs.
Unlike sedating antidepressants like trazodone, it can mimic stimulants early on.
Label does not describe Prozac as mimicking stimulants or compare to trazodone in this way.
Most cases of startup insomnia resolve within 2-4 weeks.
Label does not provide a specific resolution timeline for insomnia.
If insomnia persists beyond a month, dose adjustment or switching may be needed.
Label does not provide this explicit guidance for insomnia duration and management.
Taking it in the morning helps minimize nighttime interference.
Label does not mandate morning dosing for insomnia reduction in this wording.
User forums and reviews note trouble falling asleep or frequent waking in the first 7-14 days, sometimes with vivid dreams.
Label-based safety communication does not reference forum anecdotes.
About 14% discontinue due to this in short-term studies.
The label excerpt provided does not specify a 14% discontinuation rate for insomnia.
Start at a low dose (e.g., 10 mg) and increase gradually.
The label commonly cites starting doses around 20 mg daily; 10 mg start is not stated in the provided sections.
Avoid evenings; morning dosing aligns with its energizing profile.
The label does not provide this dosing guidance in this exact form.
Short-term aids like melatonin or therapy may help, but consult a doctor first.
Label does not endorse melatonin or sleep therapies as adjuncts for insomnia in this manner.
About 5-10% need an add-on like low-dose trazodone for sleep.
Label does not prescribe such sleep adjuncts or percentages.
Mild insomnia is expected, but seek help if it worsens depression, causes mania-like symptoms, or lasts over 4 weeks.
Label does not provide this specific progression guidance for insomnia.
Prozac is more activating than Zoloft (sertraline), with milder insomnia risk.
Label does not provide these cross-drug activating/sleep-risk comparisons.
Prozac is more activating than Lexapro (escitalopram), often neutral regarding sleep.
Label does not provide these cross-drug comparisons.
Prozac is less activating than Paxil (paroxetine), which can cause sedation.
Label does not provide cross-drug comparative activation/sedation statements.
Contradictions
Important Omissions
Boxed warning for suicidality in children/adolescents/young adults and general pediatric safety considerations.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
A few statements align with labeling (insomnia, anxiety, serotonin syndrome risk) but many AI claims are not supported or are misrepresented relative to the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Limit to statements supported by the label; remove or revise assertions about dosing specifics (e.g., 10 mg start), comparative SSRI activation, and patient anecdotes. Include explicit references to boxed warnings and clinically relevant guidance (e.g., 5.1 Boxed Warning).